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Abstract
It is well known that inbreeding increases the risk of recessive monogenic diseases, but it is
less certain whether it contributes to the etiology of complex diseases such as schizophre-
nia. One way to estimate the effects of inbreeding is to examine the association between
disease diagnosis and genome-wide autozygosity estimated using runs of homozygosity
(ROH) in genome-wide single nucleotide polymorphism arrays. Using data for schizophre-
nia from the Psychiatric Genomics Consortium (n = 21,868), Keller et al. (2012) estimated
that the odds of developing schizophrenia increased by approximately 17% for every addi-
tional percent of the genome that is autozygous (β = 16.1, CI(β) = [6.93, 25.7], Z = 3.44, p =
0.0006). Here we describe replication results from 22 independent schizophrenia case-con-
trol datasets from the Psychiatric Genomics Consortium (n = 39,830). Using the same ROH
calling thresholds and procedures as Keller et al. (2012), we were unable to replicate the
significant association between ROH burden and schizophrenia in the independent PGC
phase II data, although the effect was in the predicted direction, and the combined (original
+ replication) dataset yielded an attenuated but significant relationship between Froh and
schizophrenia (β = 4.86,CI(β) = [0.90,8.83],Z = 2.40,p = 0.02). Since Keller et al. (2012),
several studies reported inconsistent association of ROH burden with complex traits, partic-
ularly in case-control data. These conflicting results might suggest that the effects of auto-
zygosity are confounded by various factors, such as socioeconomic status, education,
urbanicity, and religiosity, which may be associated with both real inbreeding and the out-
come measures of interest.
Author Summary
It is well known that mating between relatives increases the risk that a child will have a
rare recessive genetic disease, but there has also been increasing interest and inconsistent
findings on whether inbreeding is a risk factor for common, complex psychiatric disorders
such as schizophrenia. The best powered study to date investigating this theory predicted
that the odds of developing schizophrenia increase by approximately 17% for every addi-
tional percent of the genome that shows evidence of inbreeding. In this replication, we
used genome-wide single nucleotide polymorphism data from 18,562 schizophrenia cases
and 21,268 controls to quantify the degree to which they were inbred and to test the
hypothesis that schizophrenia cases show higher mean levels of inbreeding. Contrary to
the original study, we did not find evidence for distant inbreeding to play a role in schizo-
phrenia risk. There are various confounding factors that could explain the discrepancy in
results from the original study and our replication, and this should serve as a cautionary
note–careful attention should be paid to issues like ascertainment when using the data
from genome-wide case-control association studies for secondary analyses for which the
data may not have originally been intended.
Introduction
Close inbreeding (e.g., cousin-cousinmating) is known to decrease fitness in animals[1] and to
increase risk for recessive Mendelian diseases in humans[2], a phenomenon known as
Runs of Homozygosity and Schizophrenia Replication
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inbreeding depression. Inbreeding depression is thought to occur due to evolutionary selection
against genetic variants that decrease fitness—e.g., variants that increase risk of disorders[3].
Such fitness-reducing variants should not only be more rare, but also more recessive than
expected under a neutral evolution model (i.e., show directional dominance). If so, individuals
with a greater proportion of their genome in autozygous stretches (two homologous segments
of a chromosome inherited from a common ancestor identical by descent [IBD]) should have
higher rates of disorders. This is because autozygous regions reveal the full, harmful effects of
any deleterious, recessive alleles that existed on the haplotype of the common ancestor.
Whether inbreeding increases risk for complex disorders like schizophrenia is less clear.
Previous studies have found that inbreeding is associated with higher rates of complex disor-
ders[4–9]. However, sample sizes have typically been small and the possibility that confound-
ing factors might explain the results has left the links inconclusive. Moreover, close inbreeding
accounts for fewer than 1% of marriages in industrialized countries[10], and information on
pedigrees going back many generations is difficult to collect reliably. For these reasons, investi-
gators have recently begun looking at signatures of very distant inbreeding (e.g., common
ancestry up to ~100 generations ago) using genome-wide single nucleotide polymorphism
(SNP) data in an attempt to understand whether autozygosity increases the risk to schizophre-
nia and other complex diseases[11]. Autozygosity in SNP data is typically inferred from runs of
homozygosity (ROHs): long, contiguous stretches (e.g.,> 40) of homozygous SNPs. The pro-
portion of the genome contained in such ROHs, Froh, can then be used to predict complex
traits[12–19]. Keller et al.[11] showed that Froh is the optimal method for detecting inbreeding
signals that are due to rare, recessive to partially recessive mutations, such as those thought to
occurwhen traits are under directional selection[3]. The low variation in Froh means that large
sample sizes (e.g.,>12,000) are required to uncover realistic effects of distant inbreeding on
complex diseases in samples unselected for inbreeding[11].
In 2012, Keller et al.[20] used the original Psychiatric Genomics Consortium schizophrenia
data (17 case-control datasets, total n = 21,831) to investigate whether Froh is associatedwith
increased risk of schizophrenia. The authors estimated that the odds of developing schizophrenia
increased by approximately 17% for every additional percent of the genome that is contained in
autozygous regions (β = 16.1, CI(β) = [6.93, 25.7], p = 6x10-4.) This was by far the largest study to
that date examining the association betweenFroh and any psychiatric disorder, and the signifi-
cant relationship betweenFroh and case-control status remained robust through secondary anal-
yses of various covariate combinations, common vs. rare IBD haplotypes, and SNP thresholds
used to define ROHs. These results are consistent with the hypothesis that autozygosity causally
increases the risk of schizophrenia. Nevertheless, because various confounding factors may
increase likelihoodof distant inbreeding as well as the probability of having offspring with schizo-
phrenia, these results do not imply a causal relationship. For example, parents higher on schizo-
phrenia liability may pass their higher liability to offspring and mate with more genetically
similar partners (e.g., due to decreasedmobility, educational opportunities, etc.).
The current study seeks to provide a well-powered, independent replication of Keller et al.
(2012)[20]. In light of the growing concern about publication bias[21,22] and dearth of well-
powered replications[23,24], this follow-up analysis is a necessary step in validating the Froh—
schizophrenia relationship. The present study used genome-wide SNP data from 22 indepen-
dent schizophrenia case-control datasets (n = 39,830) from the PGC[25] to further examine
the relationship between Froh and schizophrenia. Our replication attempt is an important con-
tribution to the growing body of literature examining autozygosity and psychiatric disorders,
and should help verify whether autozygosity estimated from ROHs is robustly related to
schizophrenia risk and, by extension, can help elucidate whether schizophrenia risk alleles are
biased, on average, toward recessive effects.
Runs of Homozygosity and Schizophrenia Replication
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Results
SNP data from 28,985 schizophrenia cases and 35,017 controls were collected as detailed in
Ripke et al.[25]. Quality control (QC) and analyses were conducted separately for the original
and replication datasets. The “original” dataset included subjects from the PGC’s SCZ1[26]
samples used by Keller et al[20] (n = 21,868 after QC), and the “replication” dataset contained
all subjects (n = 39,830 after QC) in the PGC SCZ2[25] samples not included in the original
Keller et al. study, making the replication dataset independent of the original dataset analyzed
in Keller et al.
Despite the number of imputed SNPs ranging from ~1.8 million to ~4.2 million in the data-
sets, there were not enough well imputed SNPs in common across all 22 datasets to conduct a
viable ROH analysis in the same way as in the original study (seeMethods). Nevertheless, Kel-
ler et al. also reported results from ROHs estimated from unimputed SNP data, and these
results were highly consistent with imputed SNPs. Therefore, our primary analyses were con-
ducted using post-QC, unimputed genotype data. We also report results on imputed SNPs (see
S5–S12 Figs and S1 Table) using slightly different QC procedures than used in the original
report (seeMethods), which do not change the conclusions below. While ROHs from the
imputed data were called from a common SNP set, ROHs from the unimputed data were called
on unique sets of SNPs for each dataset.
Keller et al.[20] found that all ROH length thresholds were significantly associated with
schizophrenia, but because ROH thresholds are ultimately arbitrary, they focused their discus-
sion on the thresholds (e.g., 110 consecutive homozygous SNPs in the unimputed data) that
maximized the schizophrenia-ROH relationship. In an attempt to follow as closely as possible
the method used by Keller et al., we report two sets of ROH results. The first approach—a
direct replication attempt of Keller et al.—definedROHs as being 110 consecutive homozy-
gous SNPs in a row (with medianMb ranging from ~1 to ~3.4 Mb, depending on sample) in
the unimputed data. Because using unimputed SNP data introduces large differences in mean
ROH length across datasets (when defined by number of consecutive homozygous SNPs) due
to varying SNP densities, we also employed a secondary replication approach using a 2.3 Mb
minimum length threshold that corresponds to 110 SNPs-in-a-row average length in the origi-
nal report. As in the original report, we also show results across all thresholds to ensure that no
results were missed.
Table 1 gives the descriptive statistics for average ROH lengths and Froh across datasets,
where ROHs were defined as 110 consecutive homozygous SNPs. There was wide variation
in average Froh and ROH lengths between datasets, a consequence of using unimputed SNP
data, which introduces more between-dataset variability in Froh and mean ROH length[20].
Across datasets, mean Froh was also higher (0.30% vs. 0.14%) and average ROH lengths shorter
(1.1–3.4Mb vs. 2.0–4.7Mb) in the replication versus original datasets. Part of the reason for
the mean Froh discrepancy seemed to be due to replication datasets being genotyped on denser
SNP chips, because this discrepancy reduced when we defined ROHs as 2.3 Mb homozygous
SNPs (0.22% vs. 0.13%; Table 1). The remaining higher average Froh in the replication datasets
appears to be due to more samples being from countries with higher overall Froh (e.g., Sweden,
Estonia, Israel) in the replication datasets; the average Froh levels were very similar across repli-
cation vs. original datasets within the same countries.
ROH burden results
For each dataset, we regressed case-control status on Froh using mixed effects logistic regres-
sion treating dataset as a random factor, and controlled for 20 principal components (PCs)
from the genomic relationship matrix[27] and two SNP quality measures (excess
Runs of Homozygosity and Schizophrenia Replication
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heterozygosity and SNP missingness; seeMethods). In Keller et al. (2012), the authors used
mixed effectsmodels to test the ROH burden association with schizophrenia. However, in the
current analysis we used fixed effect logistic regression models, treating dataset as a fixed,
because a minority of the mixed effectsmodels failed to converge. When the mixed effects
models did converge, the results were highly similar to the respective fixed effectmodels. Figs 1
and S1 show the predicted change in odds of schizophrenia risk (and 95% confidence intervals)
for every 1% increase in average Froh for each logistic regression in the replication data using
ROHs defined by either110 consecutive homozygous SNPs (Fig 1) or ROH length 2.3 Mb
(S1 Fig). The overall association between schizophrenia and Froh in the replication data was in
the predicted direction but not significant for ROHs defined as at least 110 consecutive homo-
zygous SNPs (β = 0.19, CI(β) = [−4.50,4.88],Z = 0.08, p = 0.94) or for ROHs defined as 2.3
Mb (β = 0.75, CI(β) = [−4.05,5.56],Z = 0.31, p = 0.76). The results from analyses on ROHs
called from imputed rather than raw SNP data were also non-significant (S5 Fig). As in Keller
et al., we also explored increasingly long SNP and Mb ROH thresholds to assess the stability of
the Froh-schizophrenia relationship (Figs 2 and 3). Across all thresholds, the only thresholds
that approached significant associations between Froh and schizophrenia in the replication
data were at the upper limits of the Mb-length ROH thresholds; the strongest association was
for ROHs defined as 19 Mb (β = 8.64, CI(β) = [−0.85,18.13],Z = 1.78, p = 0.07).
We conducted a series of follow-up analyses to ensure that the failure to replicate our origi-
nal report was not due to analytical error, inclusion of outlier individuals or datasets, or
Table 1. Descriptive data for the unimputed (post-QC) PGC replication data—ROHs defined as 110 consecutive homozygous SNPs or as 2.3
Mb long.
Dataset N (post-
QC)
N
cases
Site Platform ROH definition: 110 SNPs-in-a-row ROH definition: 2.3 Mb long
Avg Froh
(*100)
SD Froh
(*100)
Avg
Mb
SD
Mb
Avg Froh
(*100)
SD Froh
(*100)
Avg
Mb
SD
Mb
aarh 1699 841 Denmark I650 0.22 0.70 2.35 3.12 0.16 0.66 4.42 4.34
ajsz 2484 891 Israel I1M 0.85 0.92 2.36 2.62 0.56 0.89 4.50 3.52
asrb 664 395 Australia I650 0.13 0.32 2.07 2.94 0.10 0.31 3.79 4.13
boco 2032 1214 Germany Illum 0.14 0.50 2.61 3.72 0.11 0.50 4.38 4.82
clm2 5451 3358 UK I1M 0.11 0.37 2.30 3.21 0.10 0.36 3.73 3.98
clo3 3638 2079 UK omni 0.17 0.55 2.08 3.49 0.12 0.54 4.27 5.45
cou3 1186 508 UK omni 0.13 0.24 1.80 3.06 0.08 0.24 3.41 4.92
egcu 1374 232 Estonia omni 0.38 0.57 2.19 2.61 0.25 0.54 4.24 3.71
ersw 553 244 Sweden omni 0.30 0.55 2.04 2.52 0.18 0.50 4.19 3.85
gras 2170 1041 Germany AXI 0.25 0.73 2.00 2.58 0.15 0.67 4.73 3.92
irwt 2267 1277 Ireland A6.0 0.17 0.23 2.14 1.93 0.14 0.22 3.59 2.22
lie2 399 130 US O25 0.31 0.24 1.16 1.09 0.08 0.18 3.57 2.56
lie5 870 485 US I550 0.13 0.24 1.98 1.55 0.09 0.20 3.52 1.75
msaf 436 308 US & Israel A6.0 0.55 1.15 2.76 2.71 0.42 1.04 4.55 3.14
pewb 2327 566 Seven
countries
I1M 0.13 0.44 2.27 2.52 0.11 0.40 3.88 3.09
pews 386 150 Spain I1M 0.37 0.79 2.98 3.14 0.31 0.74 4.91 3.50
s234 3592 1558 Sweden A6.0 0.28 0.53 2.38 2.44 0.21 0.46 4.03 3.03
swe5 4286 1723 Sweden omni 0.30 0.64 2.32 3.27 0.21 0.61 4.46 4.75
swe6 2041 909 Sweden omni 0.54 0.93 2.76 3.65 0.40 0.86 5.05 4.85
top8 206 139 Norway A6.0 0.23 0.62 2.44 2.29 0.18 0.60 4.04 2.59
umeb 897 328 Sweden omni 0.76 1.34 3.21 4.44 0.60 1.27 5.84 5.78
umes 872 186 Sweden omni 1.03 1.26 3.43 4.03 0.84 1.22 5.64 4.81
doi:10.1371/journal.pgen.1006343.t001
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Fig 1. Estimated changes in odds of schizophrenia for each 1% increase in Froh (odds ratios; asterisks) and their 95%
confidence intervals (bars) across the independent replication datasets (colored according to SNP platform) and for the
total sample (black) from the unimputed SNP data, for ROHs defined as 110 consecutive homozygous SNPs. Boxes are
proportional to the square root of sample sizes (also shown at the bottom). Dataset names are on the x-axis. Only one of the
individual estimated odds ratios significantly differs from one (“clm2” dataset), and the overall effect (black) is not significant (β =
0.19, Z = 0.08, p = 0.94).
doi:10.1371/journal.pgen.1006343.g001
Fig 2. Slope estimates (the change in log odds for a 1% increase in Froh; points) and their 95% confidence intervals
(bars) of Froh from unimputed SNP data predicting schizophrenia for different SNP thresholds of calling ROHs. No
SNP homozygosity threshold was significant.
doi:10.1371/journal.pgen.1006343.g002
Runs of Homozygosity and Schizophrenia Replication
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suppressing covariates in the replication data. We reran the same analyses described above on
SNP data from the “original” report using the exact same quality control and analytic proce-
dures performed on the replication data. Results were virtually identical to those obtained in
Keller et al.’s 2012 study (S2–S4 Figs), increasing our confidence that the procedures used in
the replication attempt were identical to those used in the original analysis and that the results
from the original analysis were not due to analytic or procedural errors. We then reran analyses
in the replication data after (a) omitting individuals with very long (>30 Mb) ROHs, (b) omit-
ting only long ROHs, (c) including all combinations of covariates in the model (SNP missing-
ness, average heterozygosity, 10 or 20 principle components), and (d) including only the
longest ROH for each individual. The Froh-schizophrenia relationship remained non-signifi-
cant in these follow-up analyses (results shown in S2 Table).
We noticed that there was greater variability in Froh in the replication datasets and that this
greater variability was mostly driven by replication datasets that had n< 300. Under the prem-
ise that smaller samples might differ in genotypic or phenotypic quality, we excluded seven
samples that contained fewer than 300 cases (“egcu”, “ersw”, “lie2”, “pews”, “top8”, “umes”),
reran our baseline analysis (including all covariates mentioned above and using an ROH
threshold of 110 consecutive homozygous SNPs), but still observed a non-significant Froh-
schizophrenia relationship (β = 1.04, CI(β) = [−3.88,5.96],Z = 0.42, p = 0.68) in the predicted
direction. Therefore, this post-hoc analysis does not lend support to the possibility that small
samples in the replication set added noise to our analysis, obscuring an Froh-schizophrenia
relationship.
Although results from the replication analysis were not significant, they were in the same
direction as the original analysis. It could therefore be argued that the best estimate of the asso-
ciation betweenROHs and schizophrenia is obtained by combining the two datasets. When we
reran our analyses on the combined original + replication data (n = 61,661), all Froh associa-
tions based on ROH thresholds greater than 60 consecutive homozygous SNPs or longer than
Fig 3. Slope estimates (the change in log odds for a 1% increase in Froh; points) and their 95% confidence intervals
(bars) of Froh from unimputed SNP data predicting schizophrenia for different Mb thresholds of calling ROHs. No Mb
length thresholds reached significance.
doi:10.1371/journal.pgen.1006343.g003
Runs of Homozygosity and Schizophrenia Replication
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1 Mb were significant (Figs 4 and 5). For an ROH threshold of 110 consecutive homozygous
SNPs), we observed a significant Froh-schizophrenia relationship in the combined data (β =
4.86, CI(β) = [0.90,8.83], Z = 2.40, p = 0.02). In this combined dataset, we also used a replica-
tion status-by-Froh interaction to conclude that the Froh-schizophrenia association was only
Fig 4. Slope estimates (the change in log odds for a 1% increase in Froh; points) and their 95% confidence intervals
(bars) of Froh from the combined unimputed SNP data predicting schizophrenia for different SNP thresholds of
calling ROHs. All SNP thresholds greater than 60 SNPs-in-a-row were significant.
doi:10.1371/journal.pgen.1006343.g004
Fig 5. Slope estimates (the change in log odds for a 1% increase in Froh; points) and their 95% confidence intervals
(bars) of Froh from the combined unimputed SNP data predicting schizophrenia for different Mb thresholds of
calling ROHs. All length thresholds longer than 1 Mb were significant.
doi:10.1371/journal.pgen.1006343.g005
Runs of Homozygosity and Schizophrenia Replication
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marginally higher in the original compared to the replication datasets (interaction β = −3.98,
Z = −1.84, p = 0.07) for ROHs defined as at least 110 consecutive homozygous SNPs.
The effects of close versus distant inbreeding
To assess the relative importance of distant versus close inbreeding, we compared the effects of
short versus long ROHs. As in the original study, we chose our ROH length threshold based on
the Mb length cutoff that resulted in equal Froh variances, calculating Froh_short as the pro-
portion of the genome contained in ROHs < 8 Mb long, and Froh_long as the proportion of
the genome contained in ROHs > 8 Mb long. Although neither association was significant, the
effect of Froh_short (β = −5.06, CI(β) = [−12.08,1.95],Z = −1.42, p = 0.16), caused by autozyg-
osity arising frommore ancient common ancestors, was negative (“protective”) and in the
opposite direction of effect of Froh_long (β = 1.23, CI(β) = [−4.78,7.25],Z = 0.40, p = 0.69),
caused by autozygosity arising frommore recent common ancestors, which predicted increased
risk for schizophrenia (Fig 6).
Discussion
Despite exploring various homozygous SNP length thresholds, Mb thresholds, and combina-
tions of covariates, the findings from this study do not lend much support to the original obser-
vation of a highly significant Froh-schizophrenia association[20], and provide only equivocal
support, based on combining the original and replication data, for the hypothesis that autozyg-
osity is a risk factor for schizophrenia.
Perhaps the simplest explanation for this pattern of results is that the conclusions about dis-
tant inbreeding from the original data represent a type-I error or that the lack of replication in
the current report was a type-II error. Despite the fact that the effect in the original study was
highly significant (p = 6x10-4) and the statistical power in the replication study to detect the
observed effect size in the original study was nearly 100%, it is possible that the estimated
effects of the original analysis could have been over-estimated and/or those of the replication
analysis under-estimated, due to sampling variability. There is some support for this interpre-
tation, as there was not a significant difference in results between replication versus original
datasets (interaction p = 0.07).
An alternative explanation for the overall pattern of results has to do with the potential
influence of unmeasured confounding factors in both the original and replication analyses.
Unlike genotype frequencies, which change very slowly and are unaffected by inbreeding, ROH
levels can change substantially after even a single generation of inbreeding,making ROH anal-
yses highly susceptible to confounding factors associated with both disease risk and the degree
of inbreeding/outbreeding. For example, contrary to initial predictions, Abdellaoui et al.[28]
identified a significant and negative (“protective”) relationship between Froh and risk for
major depressive disorder (MDD) in the Dutch population. However, the authors found that
religiosity was significantly associated with both higher autozygosity and lower MDD in this
population.When religiosity was accounted for in their regression model, the original associa-
tion betweenMDD and Froh disappeared. A similar effect was detected for educational attain-
ment: highly educated individuals were more likely to migrate and mate with highly educated
and more diverse partners, making highly educated spouse pairs share less ancestry and leading
to their offspring having lower Froh[29]. Thus, assortative mating on variables such as educa-
tion or religion could subtly influence observedFroh associations, potentially affecting results
in ways that can be difficult to account for. For example, an observedFroh-schizophrenia rela-
tionship could be due to parents with a higher schizophrenia liability mating with less geneti-
cally diverse mates due to, e.g., fewer educational opportunities or lower migration rates. Thus,
Runs of Homozygosity and Schizophrenia Replication
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the causation may be reversed: schizophrenia liability in parents could cause not only higher
schizophrenia risk, but also higher Froh, in offspring rather than Froh in offspring increasing
their schizophrenia liability. Such reverse and third variable causation possibilities can only be
tested if relevant socio-demographic variables in subjects and (optimally) their parents are
collected.
The possibility of unmeasured variables confounding Froh-disorder relationships seems
particularly likely in analyses conducted on ascertained samples. Ascertainment of cases and
controls not perfectlymatched on socio-demographic factors that might affect degree of out-
breeding (e.g., socioeconomic status, education level, age, religion, urbanicity) can mask any
true Froh association and bias the observed association in either direction. Such a scenario
might explain otherwise contradictory findings in previous ROH case-control analyses
[18,28,30–36]. For example, following two studies showing that genome-wide autozygosity was
significantly associated with schizophrenia risk, including the original Keller et al. study
[13,20], two newer studies failed to replicate this association[34,35], although both replication
sample sizes (n = 3,400 and 11,244 respectively) were substantially smaller than the current
one (n = 39,830). (It should be noted that the sample used in the latter study[36] overlapped
with the samples in both the original Keller et al.[20] study and the current replication study).
Even within the same study, Froh results in ascertained samples have been inconsistent. Using
PGCMDD data, Power et al.[36] found a significant positive Froh-MDD relationship in data
from three German sites but a significant negative Froh-MDD relationship in six non-German
sites. A possible explanation for this and other such examples of heterogeneity across sites they
observed is that cases and controls differed on socio-demographic factors that were associated
with Froh, and the direction of this ascertainment bias was inconsistent across data collection
sites.
We believe that similar ascertainment biases could have affected results in the present study
as well as in the original Keller et al.[20] report. Many of the PGC schizophrenia datasets used
cases ascertained from hospitals, clinics, health surveys, and advertisements but controls from
previous biomedical research volunteers, university students, blood donors, and population
registries.While such differences in ascertainment between cases and controls are highly
unlikely to lead to allele frequency differences, and thus are of little concern to genome-wide
association studies, they could very easily lead to Froh differences due to differences in degree
of inbreeding/outbreeding in the populations from which cases and controls were drawn. Con-
trolling for ancestry principal components in this case would only help to the degree that
degree of inbreeding/outbreeding is associated with ancestry. Unfortunately, none of the other
variables that might statistically control for such biases due to differences in case/control ascer-
tainment are currently available in the PGC data collection.The PGC collection of studies was
designed for association analyses; it was not optimally designed for ancillary purposes, such as
ROH analyses.
It is important to recognize that even ascertainment biases that differ at random across sites
would substantially inflate type-I error rates because the proper degrees of freedom for the test
should be closer to the number of independent sites rather than the number of independent
cases and controls. To demonstrate this, we permuted data under the null hypothesis of no
relationship between Froh and schizophrenia in the 17 datasets from the original 2012 study by
randomly flipping case or control status within each dataset for each permutation (e.g., cases
Fig 6. Forest plot of the change in odds of schizophrenia risk for each 1% increase in Froh due to short
(< 8 Mb, blue) or long (> 8 Mb, red) ROHs for each sample in the replication. Boxes are proportional to the
square root of sample sizes, and 95% confidence intervals are indicated by the horizontal lines. Dataset names
are on the y-axis, with the estimates from the combined sample at the bottom.
doi:10.1371/journal.pgen.1006343.g006
Runs of Homozygosity and Schizophrenia Replication
PLOS Genetics | DOI:10.1371/journal.pgen.1006343 October 28, 2016 11 / 20
and control statuses in a dataset either remained the same or were flipped to the opposite sta-
tus). We then calculated the overall Froh ~ schizophrenia relationship with the same logistic
regression model and using the same covariates as in the original analysis. Across 1,000 permu-
tations, 183 p-values were significant (p< 0.05), implying a type-I error rate of 0.18 and dem-
onstrating how false conclusions about Froh relationships can be reached even when
ascertainment biases are random across multiple sites.
Conclusion
Given concerns about the false discovery rate in science[22], there has been increasing empha-
sis on the need for well-powered, direct replications of novel findings in genetics[23,37,38] and
other fields[39–41]. The current study was a well-powered, direct replication attempt that
failed to replicate an earlier finding that autozygosity arising from distant common ancestors
was significantly associated with schizophrenia. As is typical with null findings, it is difficult to
identify the reason for this failure to replicate. However, we have argued that a likely cause is
that ROH associations are highly susceptible to confounding, especially in case-control (ascer-
tained) samples. Thus, we believe that the conclusions of the original study were premature
and the true causal relationship between schizophrenia and autozygosity could be either stron-
ger/more positive (if the populations from which controls were ascertainedwere, on average,
slightly less outbred than populations from which cases were ascertained) or weaker/more neg-
ative (the reverse) than reported here. Unfortunately, we do not have the ability to test these
hypotheses directly in the current datasets, and doing so awaits either new samples in which
cases and controls are carefully matched or the collection of information that allows potential
confounders to be statistically controlled. This creates a dilemma for ROH analyses using exist-
ing case-control genome-wide data: GWAS datasets usually do not match cases and controls to
the degree necessary to rule out confounding effects on ROH analyses and typically do not col-
lect the relevant socio-demographic information necessary to control for potential confound-
ers. The current study therefore serves as a cautionary tale for analyzing ROHs in existing
ascertainedGWAS datasets. Such datasets may be perfectly adequate for their designed pur-
pose–GWAS–but may be problematic and even misleading for ROH analyses.
Methods
Psychiatric Genomics Consortium GWAS Data
Our study used 37 datasets from the Psychiatric Genomics Consortium’s SCZ2 data–these data
included 28,985 schizophrenia cases and 35,017 controls, collected from 37 sites in 13 coun-
tries. Data collection and ascertainment details are described elsewhere.[25]
Keller et al.[20] used 17 datasets from the PGC SCZ1[26] data. Several of these original 17
studies recruited additional subjects by the time of our study, necessitating two well-defined,
independent datasets: one including all of the individuals analyzed in the original 2012 study
(“original” dataset), and one containing only subjects not included in Keller et al.’s 2012 report
(the “replication” dataset, comprised of 22 studies and a total sample size of 18,562 cases and
21,268 controls after QC; see Table 1). Three of the original case-control datasets from the
PGC’s SCZ1 addedmore subjects and/or controls in SCZ2, but only two of these datasets had
enough subjects to pass QC and merit inclusion in the current study—thus there is a “top8”
dataset (N = 180) in this replication study, comprised of the samples that were added to the
“top3” dataset (N = 598) from the original 2012 study, and a “boco” dataset (N = 1,870), which
includes the new cases and controls that were added to the original “bon” dataset (N = 1,778).
For consistency with the original Keller et al. (2012) study[20], we excluded the three family-
based datasets of parent-proband trios and three East Asian datasets.
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Quality Control (QC) Procedures–Raw SNP Data
We followed the same QC procedures as Keller et al.[20]. We removed a) one individual from
any pair of individuals who were related with p^ >0.2, b) individuals with non-European ances-
try as determined by principal components analysis; c) samples with SNP missingness>0.02;
or d) samples with genome-wide heterozygosities>6 standard deviations above the mean.
SNPs were excluded if they a) deviated from Hardy-Weinberg equilibrium at p<1×10−6; b)
had missingness>0.02; or c) had a missingness difference between cases and controls>0.02.
QC Procedures–Imputed SNP Data
Early in the analysis process, we found that only including SNPs with imputation dosage r2>
.90 across all datasets, as was done in the original study[20], left us with too few SNPs with
which to conduct viable ROH analyses in the replication data. Because having ROHs of similar
length and SNP density is important for comparing present results to those from the 2012
study, we decided that having a similar number of SNPs to Keller et al.[20] was more important
than following the exact same QC procedures. Thus, to arrive at a similar number of genome-
wide SNPs in the new and old datasets, some of the QCmeasures describedbelow were differ-
ent than in the 2012 investigation.
SNPs were imputed using the 1000 Genomes reference panel[42]; imputation procedures
are described elsewhere[25]. Imputation dosages were converted to best-guess (highest poste-
rior probability) SNP calls because ROH detection algorithms require discrete SNP calls, and
extremely stringent QC thresholds were employed to achieve accuracy rates similar to those in
genotyped SNPs[43]. We excluded any imputed SNPs that were not included in the HapMap3
[44] reference panel, as done in the 2012 study. Unlike the original QC procedures, we did not
require that the dosage r2 had to be> .90 in each individual datasets.We excluded any imputed
SNPs that had a dosage r2<0.98 or>1.02 in the overall sample (calculated using average dos-
age r2 weighted by sample size) or that had MAF<0.15 within each sample (vs. .05 in original),
leaving 340,084 high-quality imputed SNPs (vs. 398,325 in original).
ROH Calling Procedures
Again, we followed the same ROH calling procedures as in Keller et al[20]. As recommended
in a separate investigation[45] by three of the authors of the present study, we chose PLINK
software[46] for its computational efficiency and superior detection of autozygous stretches.
As in the 2012 study, we pruned for LD using PLINK’s—indep flag, which ensures more uni-
form SNP coverage across the genome and reduces false autozygosity calls by removing redun-
dant markers. We pruned SNPs for LD using a VIF threshold of 10, which is equivalent to
multiple R2> 0.90 between the focal SNP and the 50 surrounding SNPs.
We called ROHs using PLINK’s—homozyg flags, defining initial ROHs as being40 homo-
zygous SNPs in a row with no heterozygote calls allowed.We required that ROHs have a den-
sity greater than 1 SNP per 200 kb, and split an ROH into two if a gap>500 kb existed between
consecutive homozygous SNPs. We then post-processed the initial ROH calls by altering the
SNPs-in-a-row threshold and the Mb length threshold; specifically, we looked at ROH calls
with a minimum of 40 to 200 consecutive homozygous SNPs in increments of 10, and ROH
calls with minimum lengths ranging from 1 to 20 Mb by increments of 1 Mb. We varied ROH
thresholds this widely to ensure that no potential effects of autozygosity were missed, but the
primary results presented here are based on two replication attempts in the unimputed data:
(a) using the same SNP thresholds that gave the most straightforward comparison with the
original report (this was 110 SNPs-in-a-row for the unimputed data, spanning ~1 to ~2.1 Mb
in the replication datasets, and 65 SNPs-in-a-row for the imputed data), and (b) using the
Runs of Homozygosity and Schizophrenia Replication
PLOS Genetics | DOI:10.1371/journal.pgen.1006343 October 28, 2016 13 / 20
physical length threshold (2.3 Mb) that corresponded to the average Mb length for 110 SNPs-
in-a row in the original report.
ROH Burden Analysis
After calling ROHs, we summed the total length of all autosomal ROHs for each individual
and divided that by the total SNP-mappable distance (2.77x109 bases) to calculate Froh. Froh,
the proportion of the genome contained in long homozygous regions, was used as the predictor
of schizophrenia case-control status in analyses describedbelow. As confounding factors such
as population stratification, SNP missingness, call quality, and plate effects can influence Froh,
we included the first 20 principle components (based on a genome relationship matrix calcu-
lated from ~30K LD-pruned SNPs), percentage of missing SNP calls in the raw data, and excess
heterozygosity in all regression models[20].We then regressed case-control status on Froh
using a mixed linear effects logistic regression model (available in the lme4 package in R ver-
sion 3.1.0), treating dataset as a random factor, to assess the overall effect of Froh on schizo-
phrenia across all sites. Some of the models with random effects did not converge; thus, for
consistency, we modeled dataset as a fixed factor for all analyses. The results frommixed linear
effectsmodels that converged were very similar to fixed effectsmodels, giving us confidence
that the fixed effects results of this analysis and the random effect results from the original Kel-
ler et al. (2012) study are commensurate. We also ran logistic regressions in each of the 22 data-
sets separately.
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